Suppr超能文献

玻璃酸钠眼内应用治疗慢性低眼压

Treatment of chronic ocular hypotony with intraocular application of sodium hyaluronate.

作者信息

Küçükerdönmez C, Beutel J, Bartz-Schmidt K U, Gelisken F

机构信息

Faculty of Medicine, Department of Ophthalmology, Baskent University, Turkey.

出版信息

Br J Ophthalmol. 2009 Feb;93(2):235-9. doi: 10.1136/bjo.2008.143834. Epub 2008 Oct 1.

Abstract

AIM

The aim of the study was to report the functional and morphological outcome of intraocular injection of sodium hyaluronate for treatment of chronic ocular hypotony (COH).

METHODS

We reviewed the digital chart records of patients with COH who had received one or more injections of intravitreal or intracameral sodium hyaluronate (1.4% or 2.3%). The changes in the best corrected visual acuity (BCVA) and intraocular pressure (IOP) after treatment were recorded.

RESULTS

Thirty-two eyes of 32 patients with a mean age of 56.8 years were analysed. Previous vitreoretinal surgery had been performed on all eyes for either ocular-penetrating trauma (six eyes), chronic uveitis (six eyes), full macular translocation (five eyes) or retinal detachment (15 eyes). Mean follow-up time after the first intraocular injection was 29.7 months. BCVA (logMAR) at the baseline and the last follow-up visit were 1.84 (SE 0.65) and 1.82 (SE 0.72), respectively (p = 0.87). The mean IOP at the baseline increased from 2.28 (SE 0.27) mmHg to 7.12 (SE 1.03) mmHg at the last visit (p<0.001). At the final follow-up, 20 eyes (62.5%) had an IOP higher than 5 mmHg and 24 eyes (75%) had an unchanged or improved BCVA.

CONCLUSIONS

Stabilisation of the IOP and vision in some eyes with COH following vitreoretinal surgery can be achieved with intraocular injection of sodium hyaluronate. Large case-series and long-term follow-up are necessary to confirm the beneficial role of intraocular sodium hyaluronate injections in such eyes.

摘要

目的

本研究旨在报告玻璃酸钠眼内注射治疗慢性低眼压(COH)的功能和形态学结果。

方法

我们回顾了接受一次或多次玻璃体内或前房内注射1.4%或2.3%玻璃酸钠的COH患者的数字病历记录。记录治疗后最佳矫正视力(BCVA)和眼压(IOP)的变化。

结果

分析了32例患者的32只眼,平均年龄56.8岁。所有眼睛均因眼球穿通伤(6只眼)、慢性葡萄膜炎(6只眼)、全黄斑转位(5只眼)或视网膜脱离(15只眼)接受过玻璃体视网膜手术。首次眼内注射后的平均随访时间为29.7个月。基线和最后一次随访时的BCVA(logMAR)分别为1.84(标准误0.65)和1.82(标准误0.72)(p = 0.87)。基线时的平均眼压从2.28(标准误0.27)mmHg升至最后一次随访时의7.12(标准误1.03)mmHg(p<0.001)。在最后随访时,20只眼(62.5%)的眼压高于5 mmHg,24只眼(75%)的BCVA未改变或有所改善。

结论

玻璃体视网膜手术后,玻璃酸钠眼内注射可使部分COH患者的眼压和视力稳定。需要大样本病例系列和长期随访来证实玻璃酸钠眼内注射在此类眼中的有益作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验